Drugs.com Releases Q4 Sales for Top 100 U.S. Drugs: Abilify Overtakes Nexium as the Top Drug by Sales

NEW YORK, Feb. 7, 2013 /PRNewswire/ -- Drugs.com, the leading online clinical drug resource, today released fourth quarter 2012 U.S. prescription sales data for the top 100 drugs.

At the close of 2012, Otsuka’s antipsychotic Abilify overtakes AstraZeneca’s acid reducer Nexium and moves into the number one spot with over $1.47 billion in quarterly sales. Sales expanded for all five front-runners over the quarter, although none reached double-digit growth. There are no changes in the top selling pharmaceutical classes, which include antipsychotics, proton pump inhibitors, and statins.

Top Five Drugs by Sales, Q4 2012

Drug Name Sales
($000)
% Change
(previous quarter)
Abilify $1,478,301 5.20%
Nexium $1,441,472 1.45%
Crestor $1,275,483 2.41%
Cymbalta $1,227,484 5.97%
Humira $1,206,377 4.70%

Crestor, Cymbalta and Humira all hold steady sales rankings compared to last quarter. Cymbalta, Eli Lilly’s antidepressant and pain modifier with over $4.4 billion in 2012 sales, is slated for patent expiration at the end of 2013. Nexium maintains exclusivity until Q2 2014, and Abilify, Crestor and Humira are all scheduled to face generic competition in either 2015 or 2016.

Top Five Sales Gains, Q4 2012

Drug Name Gain
($000)
% Change
(previous quarter)
budesonide $79,295 +42.52%
Abilify $73,075 +5.20%
Cymbalta $69,131 +5.97%
Lantus Solostar $62,028 +11.58%
Advair Diskus $56,263 +4.90%

Top Five Sales Losses, Q4 2012

Drug Name Loss
($000)
% Change
(previous quarter)
TriCor -$128,731 -41.58%
Neulasta -$29,497 -3.54%
Incivek -$26,778 -9.14%
One Touch Ultra -$24,687 -6.59%
Avonex -$20,275 -5.17%

AbbVie’s cholesterol treatment TriCor drops 53 spots with a $129 million sales decline in Q4 2012 even though it did not lose patent protection until January of 2013. Neulasta, Incivek and Avonex also report declining sales of $20 to $30 million.

“The top five brands maintained their leading positions in the last quarter of 2012.” said Philip Thornton, CEO of Drugs.com. “Fewer blockbuster brands lost exclusivity, however 2013 will bring a new round of generic competition highlighted by the expected Cymbalta patent loss later this year."

Zomig and Aciphex are additional top-selling brands expected to lose patent protection in 2013.

Detailed data on the top 100 drugs can be accessed at:

http://www.drugs.com/stats/top100/sales

About Drugs.com

Drugs.com is the leading online drug information resource with over nine million unique visitors per month (ComScore, January 2013). Providing free, independent, peer-reviewed, and up-to-date information at both consumer and professional levels, Drugs.com empowers patients and caregivers to take charge of their health and be more informed than ever before. The site includes many interactive tools and mobile apps to assist consumers, healthcare professionals and researchers, such as personal medication records, a drug interaction checker, pill identification wizard, symptom checker, pharma sales statistics and more.

For more information, visit: www.drugs.com.

Media Inquiries:
Drugs.com Press Officer
press@drugs.com
(718) 395 2473

Posted: February 2013


View comments

Hide
(web4)